Navigation Links
Jazz Pharmaceuticals Announces Reduction in Force to Reflect Streamlined Operations
Date:12/16/2008

PALO ALTO, Calif., Dec. 16 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced a reduction in force of 71 employees, or approximately 24 percent of its work force, to lower operating expenses. The company expects to record a charge of approximately $1.9 million in the fourth quarter of 2008 related to this workforce reduction. Separately, Jazz Pharmaceuticals announced today that its Chief Financial Officer, Matt Fust, has decided to leave the company at year end to pursue other professional interests. His responsibilities will be assumed by other members of the executive management team.

The reduction does not affect the company's sales force. Jazz Pharmaceuticals currently markets and sells XYREM(R) (sodium oxybate) and LUVOX CR(R). The company will continue development of JZP-6 (sodium oxybate) for the treatment of fibromyalgia syndrome. In a recent press release, the company announced positive top-line results from the first of two pivotal Phase III clinical trials of JZP-6. JZP-8, Jazz Pharmaceuticals' product candidate providing intranasal delivery of clonazepam for the treatment of acute repetitive seizures, is continuing its Phase II clinical trial.

"Concentrating our company's efforts on growing sales of our commercial products and pursuing selected development programs, while streamlining our operations, will reduce ongoing operating expenses and minimize the need for additional financing," said Samuel Saks, M.D., Chief Executive Officer of Jazz Pharmaceuticals. "We thank all of our employees for their hard work on behalf of the company and their efforts to help us provide important products for patients and physicians. In particular, I would like to thank Matt for his many contributions since the formation of the company."

About Jazz Pharmaceuticals, Inc.
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Sigma-Aldrich Corporation (NASDAQ: SIAL ... the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in ... 2014, thereby completing the U.S. HSR Act antitrust ... the Company by Merck KGaA, Darmstadt, Germany.  ... to closing the transaction, which remains subject to ...
(Date:12/22/2014)... Malvern, PA & Brussels (PRWEB) December 22, 2014 ... Education (CfPIE), the global leader of technical training ... Society for Clinical Data Management (SCDM) to ... training and certification programs —providing access to the ... The partnership extends SCDM members with 10% off when ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy & ... it has signed a letter of intent to ... developed and patented a nanotechnology-based development platform used ... that enable rapid on-site collection and testing to ... health issues in an immediate, non-invasive and cost-effective ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... reviews and editorials addressing developments and pathways related ... a provocative article exploring the role of follicle-stimulating ... treatment of prostate cancer. , The article ... possibility that there could be a connection to ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ... completed in the Phase II component of a Phase ... patients with advanced cancers. The principal investigators for the ... Cancer Research, London, England, and Dr. Geoff Hall of ...
... materials scientists at the National Institute of Standards and ... in Russia to an unexpected findingthe surprisingly strong and ... storage. Their recently reported findings* may add new scientific ... density data storage devices. The team was studying ...
... 1 Johnson & Johnson ... Department of Molecular Biology at the Max Planck Institute ... novel cancer therapies including Herceptin(R) (trastuzumab)*, is the winner ... Research. An independent committee of world-renowned scientists selected Dr. ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial 2Unexpectedly long-range effects in advanced magnetic devices 2Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 2Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 3Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 4Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 5
(Date:12/22/2014)... , Dec. 22, 2014 Research ... has announced the addition of the ... report to their offering. ... insight provides an overview of the global ... aims to control and monitor piracy by ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ... funding to expand its team and bring LaunchKey to ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in ... sensors in biomedical applications. Chemical sensors help in ... diagnosis during surgical procedures. The Global Chemical Sensor ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... might call "white graphene" may be the perfect sidekick ... in nanoscale electronics. But single-atom-thick layers of hexagonal ... Rice University,s world-class Department of Mechanical Engineering and Materials ... well. Researchers in the lab of Pulickel Ajayan, ...
... hardest workers as key pollinators for one-third of all ... half-century, with die-offs in recent years stumping scientists and ... Science Foundation (NSF) multi-institutional grant co-led by Cornell ... natural history bee collections across the United States. This ...
... Ecologists have long believed that fish tend to return to ... But researchers at Ohio State University have determined that the ... walleye, at least. Using a statistical analysis of chemicals ... calculate the percentage of walleye hatched in the Sandusky and ...
Cached Biology News:'White graphene' to the rescue 2New $1.5 million NSF grant to track bee declines and pollination 2Ear bones reveal spawning secrets of Lake Erie walleye 2Ear bones reveal spawning secrets of Lake Erie walleye 3Ear bones reveal spawning secrets of Lake Erie walleye 4
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
Presenilin 2 Immunogen: Synthetic peptide corresponding to residues 31-47 of human Presenilin 2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
SHP-2 Antibody...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
Biology Products: